Niraparib Significantly Extended Survival in Ovarian Cancer

Niraparib (Tesaro), inhibiting the PARP DNA repair pathway, significantly extended survival in both BRCA 1-2-related and other ovarian cancers.
Ovarian cancersare diagnosed in nearly %75 of cases at stage 3 or 4, locally advanced within the abdomen and spread beyond it. Almost complete surgical removal and chemotherapy control disease in nearly all patients.
However, in stage 3 and 4 disease, recurrence after successful surgery (residual tumor under 1 cm) and chemotherapy is around %70. To improve surgical success, Carboplatin and Paclitaxel, two chemotherapy drugs, are given before or afterward.
After this international standard, recurrent disease falls into two groups:
- Recurrence 6 months or later after final chemotherapy, and
- Recurrence before 6 months
Those recurring 6 months or later are called platinum-sensitive . They remain sensitive to the initial regimen or similarly effective treatments, often obtaining regression. Yet prolonged chemotherapy after recurrence is limited by fatigue and adverse effects. A major oncology goal is replacing beneficial chemotherapy with gentler maintenance causing less harm.
Precisely for recurrent, chemotherapy-sensitive ovarian cancer, the oral targeted medicine Niraparib was tested, with successful results presented at ESMO 2016 Cancer Congress. Success could change practice. At ESMO 216, detailed results were also published in New England Journal of Medicine.
Niraparib (Tesaro) inhibits a pathway in cancer-cell DNA repair mechanisms, PARP. This prevents renewal and causes cell death. This class particularly benefited hereditary (BRCA1-2) ovarian cancers and was expected effective in these groups. The study went further, proving efficacy in both BRCA1-2-related and other ovarian cancers.
Niraparib Works in Both BRCA 1-2-Related and Other Ovarian Cancers
The trial enrolled BRCA1-2 carriers, 203 patients, and noncarriers, 300, totaling 503. Among chemotherapy-responsive recurrent cases, 372 received Niraparib 300 mg and others placebo. In BRCA1-2 carriers, disease control lasted 22 months with Niraparib versus 5.5 without. In BRCA1-2 noncarriers, it lasted 13 versus 4 months. Apart from moderate blood-count reductions, no unmanageable serious adverse effects were found.
These striking, potentially practice-changing results may in the coming days receive United States Food and Drug Administration (FDA) approval, we believe. Such positive results for a new ovarian cancer medicine have delighted our patients and us oncologists alike. We are following the drug’s approval processes and will provide information at appropriate times.
Sources
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
October 8, 2016DOI: 10.1056/NEJMoa1611310
Was this article helpful?
Your feedback helps us improve our content.




Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.